Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 18/20 | 0.53 |
| ▸ | F2 | P00734 | 1/20 | 0.43 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.43 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.43 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.43 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14174412 | 1.00 | ELANE (0.53) | ELANEF2PRSS1PRSS2PRSS3 | |
| SCHEMBL2211272 | 0.92 | ELANE (0.54) | ELANECES2 | |
| SCHEMBL2213292 | 0.92 | ELANE (0.54) | ELANECES2 | |
| SCHEMBL2211805 | 0.82 | ELANE (0.58) | ELANE | |
| SCHEMBL2212581 | 0.82 | ELANE (0.49) | ELANE | |
| SCHEMBL2212579 | 0.82 | ELANE (0.49) | ELANE | |
| SCHEMBL2210201 | 0.80 | ELANE (0.47) | ELANE | |
| SCHEMBL2210196 | 0.80 | ELANE (0.47) | ELANE | |
| SCHEMBL2211242 | 0.79 | ELANE (0.48) | ELANE | |
| SCHEMBL2211557 | 0.79 | ELANE (0.46) | ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110319614-A1 | Organic Compounds | NOVARTIS AG (CH) | 2011-12-29 | — | — | US | claimed |
| EP-2099769-B1 | 6-OXO.-1, 6-DIHYDROPYRIMIDIN-2-YLS IN THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2011-07-27 | — | — | EP | claimed |
| US-20100249405-A1 | Organic Compounds | NOVARTIS AG | 2010-09-30 | — | — | US | claimed |
| EP-2099769-A1 | 6-OXO.-1, 6-DIHYDROPYRIMIDIN-2-YLS IN THE TREATMENT OF PROLIFERATIVE DISEASES | Novartis AG (CH) | 2009-09-16 | — | — | EP | claimed |
| WO-2008073305-A1 | 6-OXO.-1, 6-DIHYDROPYRIMIDIN-2-YLS IN THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2008-06-19 | — | — | WO | claimed |
| US-20110319614-A1 | Organic Compounds | NOVARTIS AG (CH) | 2011-12-29 | — | — | US | disclosed |
| US-8048886-B2 | Substituted pyrazine-3-one-derivatives as IAP inhibitors | NOVARTIS AG (CH) | 2011-11-01 | — | — | US | disclosed |
| US-8048886-B2 | Substituted pyrazine-3-one-derivatives as IAP inhibitors | NOVARTIS AG (CH) | 2011-11-01 | — | — | US | disclosed |
| US-8048886-B2 | Substituted pyrazine-3-one-derivatives as IAP inhibitors | NOVARTIS AG (CH) | 2011-11-01 | — | — | US | disclosed |
| EP-2099769-B1 | 6-OXO.-1, 6-DIHYDROPYRIMIDIN-2-YLS IN THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2011-07-27 | — | — | EP | disclosed |
| US-20100249405-A1 | Organic Compounds | NOVARTIS AG | 2010-09-30 | — | — | US | disclosed |
| US-20100249405-A1 | Organic Compounds | NOVARTIS AG | 2010-09-30 | — | — | US | disclosed |
| US-20100249405-A1 | Organic Compounds | NOVARTIS AG | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319614-A1 | Organic Compounds | XIAP, BIRC5, BIRC3 | ELANE 592/4885F2 4184/4885PRSS1 724/4885 |
| US-20100249405-A1 | Organic Compounds | XIAP, BIRC5, BIRC3 | ELANE 592/4885F2 4184/4885PRSS1 724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.